The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
![](/themes/Mirage2//images/mime2.png)
Tarih
2012Yazar
Aksu, Salih
Sahin, Fahri
Uz, Burak
Yavuz, Selim A.
Atay, Hilmi
Kelkitli, Engin
Turgut, Mehmet
Pehlivan, Mustafa
Akay, Meltem O.
Guray, Emel
Demir, Muzaffer
Kahraman, Selda
Demirkan, Fatih
Paydas, Semra
Saydam, Giiray
Haznedaroglu, Ibrahim C.
Üst veri
Tüm öğe kaydını gösterÖzet
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.